Hepatitis C Drug ANA598 Moves to Phase IIb
Share
Follow Us
Anadys Pharmaceuticals Initiates Phase IIb Study of ANA598 in HCV Patients
SAN DIEGO, Jan. 4, 2011 /PRNewswire/ — Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it has initiated the planned Phase IIb study of ANA598 in combination with pegylated interferon and ribavirin. The protocol for the study has been cleared by the United States Food and Drug Administration (FDA) and Health Canada. Patient screening has begun and patient dosing is expected to commence within the next several weeks. In the study ANA598 will be tested in both treatment-naive patients and treatment-experienced patients who failed a prior course of therapy with interferon and ribavirin. ANA598 is the Company’s direct-acting antiviral, or DAA, being developed for the treatment of hepatitis C.
“We are excited to initiate this Phase IIb study of ANA598,” said James L. Freddo, M.D., Anadys’ Senior Vice President, Drug Development and Chief Medical Officer. “By establishing safety and efficacy in a greater number of patients, including those who have failed prior HCV treatment, we hope to position ANA598 as a highly attractive HCV agent ready for Phase III development.”
Continue reading this entire article:
http://www.prnewswire.com/news-releases/anadys-pharmaceuticals-initiates-phase-iib-study-of-ana598-in-hcv-patients-112891599.html
